Tagitanlimab

Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type) . Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) [1][2].

Product Specifications

CAS Number

[2417649-97-7]

Product Name Alternative

HBM-9167; KL-A167

UNSPSC

12352203

Target

PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tagitanlimab.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

[Tagitanlimab]

Molecular Weight

(144.95 kDa)

References & Citations

[1]Lu S, et al. Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors. Oncologist. 2019 Feb;24 (Suppl 1) :S21-S30. |[2]Kaplon H, et al. Antibodies to watch in 2023. MAbs. 2023 Jan-Dec;15 (1) :2153410.